Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update

Increases capital return program to $325 million from $250 million; as of 2/27/23, approximately $170 million remains in the program Discontinuing investments...

Related Keywords

United States ,Dublin ,Ireland ,American ,Maravai Lifesciences ,Susannah Gray ,Ricke Winningham ,Theravance Biopharma ,Williamd Young ,Bloomberg ,Merrill Lynch ,American Autonomic Society ,Theravance Biopharma Inc ,Young ,Columbia University ,Company Annual Report On Form ,Company Form ,Development Rd Expenses ,Securities Exchange ,Capital Return Program ,While Viatris Inc ,Wesleyan University ,Independent Director ,Executive Vice President ,Chief Financial Officer ,Royalty Pharma ,Independent Director William ,General Meeting ,Annual General Meeting ,Chief Executive ,Autonomic Society ,Full Year Financial Results ,Financial Guidance ,Based Compensation ,New Independent Director ,Chase Securities ,Molecular Therapeutics ,Live Webcast Today ,Private Securities Litigation Reform Act ,Securities Exchange Act ,Months Ended December ,Ended December ,Annual Report ,While Viatris ,Shareholder Equity ,Virtual Poster ,Nc ,